NCT01738438View on ClinicalTrials.gov

Cabozantinib for Metastatic Triple Negative BrCa

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions
Breast Cancer
Interventions
DRUG

Cabozantinib

Trial Locations (3)

02130

Dana-Farber Cancer Institute at Faulkner Hospital, Boston

02214

Massachusetts General Hospital, Boston

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

Dana-Farber Cancer Institute

OTHER

NCT01738438 - Cabozantinib for Metastatic Triple Negative BrCa | Biotech Hunter | Biotech Hunter